Frontiers in Immunology (May 2022)
Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
- Mingchuang Zhu,
- Qingpeng Zeng,
- Tao Fan,
- Yuanyuan Lei,
- Feng Wang,
- Sufei Zheng,
- Xinfeng Wang,
- Hui Zeng,
- Fengwei Tan,
- Nan Sun,
- Qi Xue,
- Jie He,
- Jie He
Affiliations
- Mingchuang Zhu
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China
- Qingpeng Zeng
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Tao Fan
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China
- Yuanyuan Lei
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Feng Wang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Sufei Zheng
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Xinfeng Wang
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Hui Zeng
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Fengwei Tan
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Nan Sun
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Qi Xue
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- Jie He
- Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China
- Jie He
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- DOI
- https://doi.org/10.3389/fimmu.2022.909105
- Journal volume & issue
-
Vol. 13
Abstract
No abstracts available.Keywords
- lipid metabolism
- early-stage lung adenocarcinoma (LUAD)
- recurrence
- immune checkpoints(ICP)
- signature
